Abstracts tagged "Medicare"

Abstract Number: 1758 • ACR Convergence 2020
Prevalence and Incidence of Infection and Venous Thromboembolism in Rheumatoid Arthritis Patients Newly Initiating Various DMARD Classes: Real-World Analysis of 2012–2016 US Medicare Data
Robin Dore¹, Jenya Antonova², Lawrence Chang², Suying Li³, Haifeng Guo³, Yuanyuan Ji³ and Mark Genovese⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³Chronic Disease Research Group, Minneapolis, MN, ⁴Stanford University Medical Center, Palo Alto, CA
Background/Purpose: RA patients have an increased risk of infection1 and venous thromboembolism (VTE)2. Although rates of serious infection and VTE have been reported for Medicare…
Abstract Number: 0055 • ACR Convergence 2020
Racial and Sex-based Disparities in Health Care Utilization: Eye Inflammation as a Paradigm
Krati Chauhan¹ and James Rosenbaum², ¹Southern Illinois University - School of Medicine, Springfield, IL, ²Oregon Health & Science University, Portland, OR
Background/Purpose: Disparities in health care utilization based on sex, race, education, or income affect outcomes in rheumatologic care. We have used ocular inflammatory and infectious…
Abstract Number: 0181 • ACR Convergence 2020
Methotrexate Use Does Not Increase the Prevalence of Hepatic Steatosis: A Real-World Retrospective Nested Case-Control Study
Yunjung Choi¹, Chang-Hun Lee¹, Myeung-Su Lee², Chang-Hoon Lee², SoJeong Park³ and Wan-Hee Yoo⁴, ¹Jeonbuk National University Hospital, Jeonju, Republic of Korea, ²Wonkwang University Hospital, Iksan, Republic of Korea, ³Data Science Team, Hanmi Pharm. Co., Ltd, Seoul, Romania, ⁴Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea
Background/Purpose: We aimed to determine whether methotrexate (MTX) treatment in patients with rheumatoid arthritis (RA) leads to the development of nonalcoholic fatty liver (NAFL).Methods: Data…
Abstract Number: 258 • 2019 ACR/ARP Annual Meeting
Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus
Geyanne Lui¹, Mangala Rajan ¹, Lisa Kern ¹, Laura Pinheiro ¹, Monika Safford ¹, Jeffrey Curtis ² and Iris Navarro-Millan ¹, ¹Weill Cornell Medicine, New York, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Medicare beneficiaries who are disabled (coverage by the Social Security Disability Insurance (SSDI)) with rheumatoid arthritis (RA) and diabetes mellitus (DM) and under 65…
Abstract Number: 953 • 2019 ACR/ARP Annual Meeting
Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012–2016 US Medicare Data
Robin Dore¹, Lawrence Chang ², Yuanyuan Ji ³, Suying Li ³, Jenya Antonova ² and Mark Genovese ⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³Chronic Disease Research Group, Minneapolis, MN, ⁴Stanford University, Stanford, CA
Background/Purpose: In RA patients not meeting treat-to-target goals despite treatment with a biologic (b)DMARD, ACR guidelines1 recommend using other targeted immunomodulators (TIM): TNF-α inhibitor (TNFi),…
Abstract Number: 1426 • 2019 ACR/ARP Annual Meeting
Impact of TNF Inhibitor Cycling with Adalimumab and Etanercept vs Switching to Tofacitinib
James Harnett¹, Timothy Smith ¹, John Woolcott ², David Gruben ³ and Christopher Murray ², ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Collegeville, PA, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. It was approved for RA by the US FDA in Nov 2012. TNFi…
Abstract Number: 2333 • 2019 ACR/ARP Annual Meeting
Risk of Incident Myocardial Infarction Among Disabled Patients with Rheumatoid Arthritis Who Were Beneficiaries of the Social Security Disability Insurance
Iris Navarro-Millan¹, Mangala Rajan ¹, Geyanne Lui ¹, Lisa Kern ¹, Laura Pinheiro ¹, Sebastian E. Sattui ², Lisa Mandl ³, Fenglong Xie ⁴, Jeffrey Curtis ⁵ and Monika Safford ¹, ¹Weill Cornell Medicine, New York, ²Hospital for Special Surgery, New York, ³Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, ⁴University of Alabama at Birmingham, Birmingham, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with RA have high risk for myocardial infarction (MI). A meta-analysis showed that the age and sex adjusted pooled relative risk of MI…
Abstract Number: 293 • 2018 ACR/ARHP Annual Meeting
Temporal Trends and Factors Associated with Bisphosphonate Drug Holidays
Jeffrey R. Curtis¹, Rui Chen¹, Tarun Arora¹, Shanette Daigle¹, Robert Matthews¹, Huifeng Yun¹, Nicole Wright², Ayesha Jaleel³, Elizabeth Delzell⁴ and Kenneth Saag⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmngham, AL, ⁴Retired - University of Alabama at Birmingham, Birmingham, AL, ⁵UAB, Birmingham, AL
Background/Purpose: Safety concerns related to osteoporosis (OP) medication use and temporary or permanent cessation of bisphosphonate therapy (e.g. ‘drug holidays’) have generated appreciable attention in…
Abstract Number: 519 • 2018 ACR/ARHP Annual Meeting
Marginal Structure Modeling of Association between Disease Activity and Hospitalized Infection Among Patients in a Rheumatoid Arthritis Registry
Huifeng Yun¹, Lang Chen¹, Jason Roy², Jeffrey D. Greenberg³ and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania, Philadelphia, PA, ³Hopital Hautepierre, Strasbourg, France
Background/Purpose: Higher disease activity might be associated with a higher risk of developing infections among patients with rheumatoid arthritis (RA). Since no randomized trial has…
Abstract Number: 885 • 2018 ACR/ARHP Annual Meeting
Herpes Zoster in Tofacitinib Users with and without Concomitant Methotrexate and Glucocorticoids
Jeffrey R. Curtis¹, Fenglong Xie¹, Sasha Bernatsky², Shuo Yang¹, Lang Chen¹, Huifeng Yun¹ and Kevin Winthrop³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Rheumatology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Oregon Health and Science University, Portland, OR
Background/Purpose: An increased incidence of herpes zoster (HZ) has been observed with Janus kinase inhibitors such as tofacitinib (TOF). However, among TOF users, a potentially…
Abstract Number: 894 • 2018 ACR/ARHP Annual Meeting
Cancer Risk in Ankylosing Spondylitis in United States Medicare Beneficiaries: Detection of a Chronic Non Steroidal Anti-Inflammatory Drug Use Signature
Sara Alehashemi¹ and Michael Ward², ¹Rheumatology, National Institutes of Health, Bethesda, MD, ²National Institutes of Health, Bethesda, MD, USA, Bethesda, MD
Background/Purpose: Few studies have examined risk of cancer in ankylosing spondylitis (AS) since the end of the radiation therapy era. With greater use of biologics,…
Abstract Number: 1242 • 2018 ACR/ARHP Annual Meeting
Rheumatologists Participating in the RISE Registry Succeeded in the First Year of the Merit-Based Incentive Payment System (MIPS)
Tracy Johansson¹, Ryan Larosa², Rachel Myslinski³, Norlita Brown¹, Lindsay Lewis¹ and Jinoos Yazdany⁴, ¹Practice, Advocacy & Quality, American College of Rheumatology, Atlanta, GA, ²American College of Rheumatology, Atlanta, GA, ³Practice, Advocacy, & Quality, American College of Rheumatology, Atlanta, GA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Under the Medicare Access and CHIP Reauthorization Act (MACRA), rheumatologists face financial repercussions through the Merit-Based Incentive Payment System (MIPS) based on performance on…
Abstract Number: 2132 • 2018 ACR/ARHP Annual Meeting
All-Cause Mortality, Hospitalization, and Systemic Lupus Erythematosus (SLE) Related Complications in 2011-2015 Medicare Beneficiaries with SLE
Suying Li, Yi Peng, Tingting Gong, Kimberly M. Nieman and David T. Gilbertson, Minneapolis Medical Research Foundation, Chronic Disease Research Group, Minneapolis, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at higher risk of complications such as heart attack and renal disease. We aimed to estimate all-cause…
Abstract Number: 2176 • 2018 ACR/ARHP Annual Meeting
The Association of Gout with Incident Giant Cell Arteritis in Older Adults
Jasvinder A. Singh and John Cleveland, Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis that affects large and medium sized arteries in people 50 years or older. Gout, the most common…
Abstract Number: 2226 • 2018 ACR/ARHP Annual Meeting
Gout and the Risk of Incident Dementia in the Elderly: A Medicare Claims Study
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The pursuit of a link between gout/hyperuricemia and dementia has led to contradictory results. Most observational studies, including population-based studies, showed that hyperuricemia was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].